PMC:7161517 / 33101-33323 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T90","span":{"begin":91,"end":94},"obj":"Body_part"},{"id":"T91","span":{"begin":166,"end":169},"obj":"Body_part"}],"attributes":[{"id":"A90","pred":"uberon_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A91","pred":"uberon_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"}],"text":"Based on our review, we hypothesize cardiovascular patients with COVID-19 should remain on RAS inhibitors because of the protective effects of the ACE2 pathway until RAS blockade is proven to increase the risk of COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T185","span":{"begin":65,"end":73},"obj":"Disease"},{"id":"T186","span":{"begin":213,"end":221},"obj":"Disease"}],"attributes":[{"id":"A185","pred":"mondo_id","subj":"T185","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A186","pred":"mondo_id","subj":"T186","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Based on our review, we hypothesize cardiovascular patients with COVID-19 should remain on RAS inhibitors because of the protective effects of the ACE2 pathway until RAS blockade is proven to increase the risk of COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T338","span":{"begin":91,"end":94},"obj":"Chemical"},{"id":"T339","span":{"begin":95,"end":105},"obj":"Chemical"},{"id":"T340","span":{"begin":166,"end":169},"obj":"Chemical"}],"attributes":[{"id":"A338","pred":"chebi_id","subj":"T338","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A339","pred":"chebi_id","subj":"T339","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A340","pred":"chebi_id","subj":"T340","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"}],"text":"Based on our review, we hypothesize cardiovascular patients with COVID-19 should remain on RAS inhibitors because of the protective effects of the ACE2 pathway until RAS blockade is proven to increase the risk of COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T197","span":{"begin":0,"end":222},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Based on our review, we hypothesize cardiovascular patients with COVID-19 should remain on RAS inhibitors because of the protective effects of the ACE2 pathway until RAS blockade is proven to increase the risk of COVID-19."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1059","span":{"begin":36,"end":50},"obj":"UBERON:0004535"},{"id":"T1060","span":{"begin":65,"end":73},"obj":"SP_7"},{"id":"T1061","span":{"begin":95,"end":105},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T1062","span":{"begin":147,"end":151},"obj":"G_3;PG_10;PR:000003622"},{"id":"T1063","span":{"begin":213,"end":221},"obj":"SP_7"},{"id":"T42119","span":{"begin":65,"end":73},"obj":"SP_7"},{"id":"T24575","span":{"begin":36,"end":50},"obj":"UBERON:0004535"},{"id":"T78530","span":{"begin":65,"end":73},"obj":"SP_7"},{"id":"T40154","span":{"begin":95,"end":105},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T60460","span":{"begin":147,"end":151},"obj":"G_3;PG_10;PR:000003622"},{"id":"T33728","span":{"begin":213,"end":221},"obj":"SP_7"}],"text":"Based on our review, we hypothesize cardiovascular patients with COVID-19 should remain on RAS inhibitors because of the protective effects of the ACE2 pathway until RAS blockade is proven to increase the risk of COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1362","span":{"begin":147,"end":151},"obj":"Gene"},{"id":"1368","span":{"begin":51,"end":59},"obj":"Species"},{"id":"1374","span":{"begin":65,"end":73},"obj":"Disease"},{"id":"1375","span":{"begin":213,"end":221},"obj":"Disease"}],"attributes":[{"id":"A1362","pred":"tao:has_database_id","subj":"1362","obj":"Gene:59272"},{"id":"A1368","pred":"tao:has_database_id","subj":"1368","obj":"Tax:9606"},{"id":"A1374","pred":"tao:has_database_id","subj":"1374","obj":"MESH:C000657245"},{"id":"A1375","pred":"tao:has_database_id","subj":"1375","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Based on our review, we hypothesize cardiovascular patients with COVID-19 should remain on RAS inhibitors because of the protective effects of the ACE2 pathway until RAS blockade is proven to increase the risk of COVID-19."}